Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2

Conditions

Polycythemia Vera 5Thrombocythemia, Essential 3Primary Myelofibrosis 3Myeloproliferative Disorders 2Hodgkin Disease 2Multiple Myeloma 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

ruxolitinib 21Azacitidine 5ponatinib 4parsaclisib 4nilotinib 4itacitinib 4anagrelide 3Phlebotomy 3Imatinib Mesylate 3INCB039110 3Aspirin 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3venetoclax 2pemigatinib 2luspatercept 2imetelstat 2givinostat hydrochloride 2givinostat 2fedratinib 2asciminib 2INCB057643 2Gemcitabine 2GRN163L peptide 2spartalizumab 1sonidegib 1selinexor 1sabatolimab 1rucaparib 1pembrolizumab 1navitoclax 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Myeloproliferative Disorders × givinostat hydrochloride × Clear all
NCT01761968 2025-04-30

Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms

Italfarmaco

Phase 2 Active not recruiting
90 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT01901432 2019-07-30

A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera

Italfarmaco

Phase 1/2 Completed
48 enrolled 28 charts
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡